Evidence map›Paper›PMID 41007155›Full record

ArticleBioengineering (Basel, Switzerland)2025

Improving Efficacy and Reducing Systemic Toxicity: An In Vitro Study on the Role of Electrospun Gelatin Nanofiber Membrane for Localized Melanoma Treatment.

Jason Sun, Yi-Chung Lai, Bing-Wu Shee, Chih-Hsiang Fang, Ching-Yun Chen, Jui-Sheng Sun

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jason SunCarmel Catholic High School, One Carmel Parkway, Mundelein, IL 60060, USA.
Yi-Chung LaiDepartment of Orthopedic Surgery, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 10002, Taiwan.
Bing-Wu SheeDepartment of Orthopedic Surgery, Landseed International Hospital, No. 77, Guangtai Road, Pingzhen District, Taoyuan 324609, Taiwan.
Chih-Hsiang FangDepartment of Orthopedic Surgery, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 10002, Taiwan.ORCID 0000-0002-7797-6584
Ching-Yun ChenDepartment of Biomedical Sciences & Engineering, National Central University, No. 300, Zhongda Rd., Zhongli District, Taoyuan 320317, Taiwan.ORCID 0000-0001-5218-5121
Jui-Sheng SunDepartment of Orthopedic Surgery, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 10002, Taiwan.ORCID 0000-0001-6549-2171

Funding

National Science and Technology Council, Taipei, Taiwan, ROC NSTC 112-2314-B-039 -049 -MY2
6 · The paper itself

Abstract

Malignant melanoma is a highly metastatic skin cancer, representing about 5% of all cancer diagnoses in the United States. Conventional chemotherapy often has limited effectiveness and severe systemic side effects. This study explores a localized, topical delivery system using cisplatin-loaded nanomembranes as a safer and more targeted alternative. Cell viability assays established the safe cisplatin concentrations for tissue culture. Gelatin-based nanomembranes incorporating cisplatin were fabricated via electrospinning. Biocompatibility and therapeutic efficacy were tested by applying the membranes to cultured melanoma and normal skin cells. Controlled drug release profiles were evaluated by adjusting cross-linking times. Cisplatin concentration between 3.125 and 12.5 µg/mL were found safe. Nanomembranes with these doses effectively eliminated melanoma cells with minimal harm to healthy skin cells. Drug-free membranes showed high biocompatibility. Cross-linking duration allowed tunable and stable drug release. Cisplatin-loaded gelatin nanomembranes offer a promising topical therapy for melanoma, enhancing drug targeting while reducing systemic toxicity. This approach may serve as a cost-effective alternative to systemic treatments like immunotherapy. Future research will focus on in vivo testing and clinical application.

Indexed as

chemotherapycisplatindrug deliverygelatin nanomembranemelanoma

Identifiers

PMID41007155
PMCPMC12467250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.